Nanobiotix (NBTX) Common Equity (2020 - 2025)

Nanobiotix's Common Equity history runs 6 years deep, the most recent figure standing at -$98.3 million for Q4 2025.

• On a quarterly basis, Common Equity fell 40.06% year-over-year to -$98.3 million in Q4 2025; TTM through Dec 2025 was -$98.3 million, a 40.06% decrease from a year earlier, with the FY2025 full-year figure at -$95.4 million, down 35.95% from the prior year.
• Common Equity fell to -$98.3 million in Q4 2025 per NBTX's latest filing, from -$78.1 million in the prior quarter.
• Across five years, Common Equity topped out at $49.9 million in Q2 2021 and bottomed at -$98.3 million in Q4 2025.
• The 5-year median for Common Equity is -$25.5 million (2024), against an average of -$27.6 million.
• Across the five-year window, Common Equity jumped 92.81% in 2023 and sank 3440.72% in 2024, its largest moves.
• Year by year, Common Equity stood at $30.6 million in 2021, then slumped by 190.03% to -$27.6 million in 2022, then soared by 92.81% to -$2.0 million in 2023, then sank by 3440.72% to -$70.2 million in 2024, then sank by 40.06% to -$98.3 million in 2025.
• Per Business Quant, the three latest NBTX Common Equity figures stand at -$98.3 million (Q4 2025), -$78.1 million (Q2 2025), and -$70.2 million (Q4 2024).